[Short-term chemotherapy of leprosy using the combination rifampicin + cotrimoxazole + isoniazid].
With the fixed combination RMP + SXT + INH an objective and subjective improvement was obtained within two months, even in severe LL-cases. Treatment resulted in final and relapse-free cure. In the majority of patients the typical erythematous infiltrative oedematous skin processes disappeared within the two months of treatment, in some of them (three of 21) within the six-month follow-up period. Lepromas (15 cases) disappeared in two patients within the two months of treatment. In the sixth month of the follow-up period nine patients were free from lepromas. In another six cases they subsided in the course of the following months. Reactions occurred in 13 patients, in part during treatment, in part during the follow-up period. Three of them were reversal reactions. Chemotherapy was not interrupted. When required, corticosteroids or thalidomide were given in addition. Erythema nodosum leprosum (17 cases) quickly subsided under treatment. Tolerance and compliance were excellent. The subjective minor "side effects" were not specific and cannot clearly be attributed to the medication. The major advantage of the combination RMP + INH + SXT described in this paper lies in the considerably reduced treatment duration (two to four months instead of two years), the rapid disappearance of the symptoms typical of leprosy, the high tolerance, the ease of application as fixed combination and the absence of relapses. So far the patients have been followed up for two years. Through the short treatment duration the cost of treatment is considerably reduced. The new combination allows outpatient treatment and is universally applicable. The patient can maintain his social and professional habits.
Freerksen
E
E
Departamento de Lepra, Asunción, Paraguay.
Alvarenga
A E
AE
Leguizamon
O
O
de Morra
M V
MV
von Ballestrem
W
W
Reyes
L A
LA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage*; D007917:Leprostatic Agents / Q000627:therapeutic use*; D015440:Leprosy, Lepromatous / Q000188:drug therapy*; D008297:Male; D012293:Rifampin / Q000008:administration & dosage*; D013997:Time Factors; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage*
D004338:Drug Combinations; D007917:Leprostatic Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D007538:Isoniazid; D012293:Rifampin
Kurzzeitchemotherapie der Lepra mit der Kombination Rifampicin + Cotrimoxazol + Isoniazid.